Laura Hagerty Bio

Dr. Hagerty has spent more than a decade pursuing therapies for muscular dystrophy. She began her career in drug development as a preclinical pharmacologist with Acceleron Pharma and later with the Skeletal Muscle Metabolism Discovery Unit at GlaxoSmithKline.  She is currently the Vice President, Research of ReveraGen BioPharma Inc.  In 2024, she co-founded HaliGene Therapeutics Inc. where she fulfills the role of Chief Scientific Officer, guiding the overall scientific and regulatory strategy.

Prior to joining HaliGene, she served as Scientific Portfolio Director at Muscular Dystrophy Association where she managed strategic investment in basic and translational research for Duchenne and related muscular dystrophies. Dr. Hagerty received her B.S. in Chemistry from Allegheny College and her Ph.D. in Pharmacology from Duke University.